GL1X · GenesisL1 explorer

MolNFT v1 · #188319 · protein

Crystal structure of shikimate-3-phosphate and glyphosate bound 3- phosphoshikimate 1-carboxyvinyltransferase from klebsiella pneumoniae

7TM6 · 3-phosphoshikimate 1-carboxyvinyltransferase: “Crystal structure of shikimate-3-phosphate and glyphosate bound 3- phosphoshikimate 1-carboxyvinyltransferase…”. X-ray diffraction, 2 ligands (S3P, GPJ), 5 pockets (best druggability…

PDB
7TM6
Type
protein
Length
853 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
3-phosphoshikimate 1-carboxyvinyltransferase
EC
2.5.1.19
UniProt
A0A0H3GV01
Ligands
S3P, GPJ
Pockets
5 · best druggability 0.75

Structure

x-ray diffraction · 2 distinct chains · 35% helix, 27% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A3-phosphoshikimate 1-carboxyvinyltransferase (EC 2.5.1.19)protein42636% helix, 26% strandA0A0H3GV01
B3-phosphoshikimate 1-carboxyvinyltransferase (EC 2.5.1.19)protein42735% helix, 27% strandA0A0H3GV01

Ligands and binding sites

  • S3P · Shikimate-3-phosphate · ligand · 2 copies · chains A, B
  • GPJ · Glyphosate · ligand · 2 copies · chains A, B
  • 1PE · Pentaethylene glycol · additive · 3 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1940.750.9730S3P, GPJ
2760.720.9728S3P, GPJ
33620.530.7347empty
4600.300.7513empty
5550.280.7516empty

Interfaces

1 interface between chains.

  • A–B · 178 Ų buried · 1 hydrogen bond · protein-protein

Compared structures

  • 7TM6 · Crystal structure of shikimate-3-phosphate and glyphosate bound 3-phosphoshikimate… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.